Shilpa Medicare jumps as its arm gets CEP from EDQM for Ursodeoxycholic Acid API
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Shilpa Medicare is currently trading at Rs. 694.25, up by 12.15 points or 1.78% from its previous closing of Rs. 682.10 on the BSE.
The scrip opened at Rs. 682.10 and has touched a high and low of Rs. 739.90 and Rs. 682.10 respectively. So far 68254 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 739.90 on 1-Aug-2024 and a 52 week low of Rs. 296.45 on 26-Oct-2023.
Last one week high and low of the scrip stood at Rs. 739.90 and Rs. 660.00 respectively. The current market cap of the company is Rs. 6790.11 crore.
The promoters holding in the company stood at 44.39%, while Institutions and Non-Institutions held 16.69% and 38.92% respectively.
Shilpa Medicare’s subsidiary -- Shilpa Pharma Lifesciences has received certificate of suitability (CEP) from EDQM (European Directorate for the Quality of Medicines & Healthcare) for API, Ursodeoxycholic Acid.
Ursodeoxycholic acid or ursodiol is a naturally occurring bile acid that is used to dissolve cholesterol gall stones and to treat cholestatic forms of liver diseases including primary biliary cirrhosis. Ursodiol has been linked to rare instances of transient and mild serum aminotransferase elevations during therapy and to rare instances of jaundice and worsening of liver disease in patients with preexisting cirrhosis.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
